SLC5A2 and endothelial dysfunction: By reducing endothelial cell activation, promoting direct vasorelaxation, and addressing endothelial dysfunction or the expression of pro-atherogenic cells and molecules, SGLT2 inhibitors reduce arterial stiffness and vascular resistance [25].